ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating

Core Insights - ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is recognized by Wall Street analysts as one of the stocks expected to rebound, with Roth MKM maintaining a Buy rating and a price target of $30 for the stock [1] Group 1: Regulatory Approvals and Product Launch - The National Medical Products Administration (NMPA) in China has approved neffy 2 mg, an epinephrine nasal spray, for emergency treatment of Type 1 allergic reactions and anaphylaxis, applicable to adults and children weighing at least 30 kilograms [2] - ARS Pharmaceuticals has an exclusive licensing agreement with Pediatrix Therapeutics for the commercialization of neffy in China, which includes a final regulatory milestone payment of $4 million and potential additional sales-based milestone payments of up to $80 million [3] - The company will manufacture and supply neffy to Pediatrix in China at cost and expects the product to be available in the spring of 2026 [4] Group 2: Future Plans and Market Strategy - ARS Pharmaceuticals and Pediatrix plan to file for approval of a neffy 1 mg dose for children weighing more than 15 kilograms and less than 30 kilograms in the upcoming months [4] - The company is focused on developing treatments for allergies that could lead to anaphylaxis, indicating a strategic emphasis on addressing severe allergic reactions [5]